Immunome
IMNM
Market cap $935M

10.75 USD

+0.15

1.42%

At close Jul 30, 4:00 PM EDT

After hours

10.75

+0.00

0.00%

1 day

1.42%

5 days

-5.95%

1 month

15.59%

3 months

22.30%

6 months

2.28%

Year to date

2.09%

1 year

-30.42%

5 years

-20.07%

10 years

-20.07%

About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Employees: 131

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

338% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 16

135% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 17

18% more funds holding

Funds holding: 120 [Q4 2024] → 142 (+22) [Q1 2025]

3.08% more ownership

Funds ownership: 85.41% [Q4 2024] → 88.49% (+3.08%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

8% less capital invested

Capital invested by funds: $566M [Q4 2024] → $518M (-$47.9M) [Q1 2025]

98% less call options, than puts

Call options by funds: $449K | Put options by funds: $29.1M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IMNM.

See Analyst Rankings

Financial journalist opinion

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 125,500 shares of common stock to 8 new employees under the Company's 2024 Inducement.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Zacks Investment Research

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 173,000 shares of common stock to 13 new employees under the Company's 2024 Inducemen.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.

Immunome to Present at Upcoming Investor Conferences

Zacks Investment Research

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy

Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy

Zacks Investment Research

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We remain on track to share topline data for the RINGSIDE trial of varegacestat in the s.

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™